FGFR2 and cholangiocarcinoma: Pemigatinib (PEMAZYRETM) and Infigratinib (TRUSELTIQTM) received approval by FDA for the treatment of advanced unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangement, and Erdafitinib (Balversa) for treatment of metastatic urothelial carcinoma with FGFR2 and FGFR3 genetic aberrations [58].